Advanced prostate cancer patients who weretreated with daily doses of the LHRH agonists had a 75% decrease in serum testosteronelevels, a decrease or normalization of plasma acid phosphatase levels, and a significantdecrease in cancer-associated bone pain (Tolis etal. 1982). Here, GNRH1 is linked to prostate carcinoma.